Catamaran Bio

Alvin Shih, M.D., CEO

April 20 | 4:30pm | Gaudi 2 Ballroom

Cambridge, MA


Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering.

By using this website you agree to accept our Privacy Policy and Terms & Conditions